Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of [¹⁴C]-LY3023414 in Healthy Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02575703
Recruitment Status : Completed
First Posted : October 15, 2015
Last Update Posted : November 23, 2015
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
This type of study is called a radiolabeled study. For this study, LY3023414 has been specially prepared to contain the radioactive carbon atom [¹⁴C]. [¹⁴C] is a naturally occurring radioactive form of the element carbon. Adding a low dose of radiation to the study drug does not change how the drug works but helps to identify when the drug appears in the blood, urine, breath, and stool after it is given. The study will last about 15 days for each participant, not including screening. Screening is required within 28 days prior to enrollment. This study is for research purposes only and is not intended to treat any medical condition.

Condition or disease Intervention/treatment Phase
Healthy Drug: [¹⁴C]-LY3023414 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Disposition of [¹⁴C]-LY3023414 Following Oral Administration in Healthy Subjects
Study Start Date : October 2015
Actual Primary Completion Date : November 2015
Actual Study Completion Date : November 2015

Arm Intervention/treatment
Experimental: [¹⁴C]-LY3023414
Single oral dose of [¹⁴C]-LY3023414 administered on Day 1
Drug: [¹⁴C]-LY3023414
LY3023414 in solution containing approximately 100 microCi [¹⁴C]-LY3023414




Primary Outcome Measures :
  1. Urinary Excretion of LY3023414 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered [ Time Frame: Baseline up to 144 hours postdose ]
  2. Fecal Excretion of LY3023414 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered [ Time Frame: Baseline up to 144 hours postdose ]

Secondary Outcome Measures :
  1. Plasma Pharmacokinetics of LY3023414 and Radioactivity Maximum Observed Concentration (Cmax) [ Time Frame: Baseline up to 144 hours postdose ]
  2. Plasma Pharmacokinetics of LY3023414 and Radioactivity Time of Maximum Observed Concentration (Tmax) [ Time Frame: Baseline up to 144 hours postdose ]
  3. Plasma Pharmacokinetics of LY3023414 and Radioactivity Area Under the Concentration Versus Time Curve (AUC) [ Time Frame: Baseline up to 144 hours postdose ]
  4. Relative Abundance of LY3023414 and the Metabolites of LY3023414 as Measured by Percentage of Sample Radioactivity in Plasma, Feces, Urine [ Time Frame: Baseline up to 144 hours postdose ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy men or women

    • Male participants: Will be sterile (including vasectomy), confirmed by documentation. Men who are sexually active with a pregnant partner agree to use a condom for 91 days from the time of dosing
    • Female participants: Women not of childbearing potential due to surgical sterilization (at least 6 months after hysterectomy with or without bilateral oophorectomy or at least 6 months after tubal ligation) confirmed by medical history or menopause. Postmenopausal women include women with spontaneous amenorrhea for at least 12 months, not induced by a medical condition such as anorexia nervosa and not taking medications during the amenorrhea that induced the amenorrhea (eg, oral contraceptives, hormones, gonadotropin releasing hormone, anti-estrogens, selective estrogen receptor modulators, or chemotherapy) and a follicle-stimulating hormone level greater than 40 milli international units per milliliter (mIU/mL)
  • Have a body mass index (BMI) of 18.5 to 32.0 kilograms per meter square (kg/m²)
  • Have clinical laboratory test results within normal reference range for the population or investigator site
  • Have venous access sufficient to allow for blood sampling

Exclusion Criteria:

  • Have participated in a [¹⁴C]-study within the last 6 months prior to admission for this study. The total 12-month exposure from this study and a maximum of one other previous [¹⁴C]-study within 6 to 12 months of this study must be within the Code of Federal Regulations (CFR) recommended levels considered safe: Less than 5000 millirem (mrem)/year whole body exposure.
  • Exposure to significant diagnostic, therapeutic, or employment-related radiation within 12 months prior to dosing (eg, serial x-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring)
  • Are participants who have previously completed or withdrawn from this study or any other study investigating LY3023414, and have previously received the investigational product
  • Have known allergies to LY3023414, related compounds, or any components of the formulation
  • Regularly use known drugs of abuse and/or show positive findings on urinary drug testing
  • Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies
  • Show evidence of hepatitis C and/or positive hepatitis C antibody
  • Show evidence of hepatitis B and/or positive hepatitis B surface antigen
  • Intend to use over-the-counter or prescription medication within 7 days prior to dosing
  • Have donated blood of more than 500 milliliter (mL) within the last month
  • Have an average weekly alcohol intake that exceeds 21 units per week, or are unwilling to stop alcohol consumption from 48 hours prior to admission and while resident in the Clinical Research Unit (CRU)
  • Have consumed herbal supplements, grapefruits or grapefruit-containing products, Seville oranges or Seville orange-containing products, star fruit or star fruit-containing products within 7 days prior to dosing or intend to consume during the study
  • Are unwilling to refrain from consuming xanthine-containing food and drink from 48 hours prior to admission until discharge from the CRU
  • Have a defecation pattern less than once per day or acute constipation within 3 weeks prior to admission
  • Have a history of clinically significant adverse drug reactions or "drug allergy" to more than 3 types of systemically administered medications

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02575703


Locations
Layout table for location information
United States, Wisconsin
Covance Clinical Research Inc
Madison, Wisconsin, United States, 53704
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company

Layout table for additonal information
Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT02575703     History of Changes
Other Study ID Numbers: 15697
I6A-EW-CBBC ( Other Identifier: Eli Lilly and Company )
First Posted: October 15, 2015    Key Record Dates
Last Update Posted: November 23, 2015
Last Verified: November 2015